ID: ALA3327388

Max Phase: Preclinical

Molecular Formula: C23H30N2O6

Molecular Weight: 430.50

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  COc1cc([C@H](CC=C(C)C)OC(=O)CC(C)C)c(OC)c2c1/C(=N/O)C=C/C2=N\O

Standard InChI:  InChI=1S/C23H30N2O6/c1-13(2)7-10-18(31-20(26)11-14(3)4)15-12-19(29-5)21-16(24-27)8-9-17(25-28)22(21)23(15)30-6/h7-9,12,14,18,27-28H,10-11H2,1-6H3/b24-16+,25-17+/t18-/m0/s1

Standard InChI Key:  KSNHMNQDRBNSEV-IMSPSDRLSA-N

Associated Targets(Human)

DU-145 (51482 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MCF7 (126967 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
K562 (73714 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HCT-15 (51914 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Fibroblast (163371 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

B16-F0 (142 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 430.50Molecular Weight (Monoisotopic): 430.2104AlogP: 4.62#Rotatable Bonds: 8
Polar Surface Area: 109.94Molecular Species: ACIDHBA: 8HBD: 2
#RO5 Violations: 0HBA (Lipinski): 8HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: 5.02CX Basic pKa: CX LogP: 4.01CX LogD: 1.77
Aromatic Rings: 1Heavy Atoms: 31QED Weighted: 0.27Np Likeness Score: 1.01

References

1. Wang R, Zhang X, Song H, Zhou S, Li S..  (2014)  Synthesis and evaluation of novel alkannin and shikonin oxime derivatives as potent antitumor agents.,  24  (17): [PMID:25127868] [10.1016/j.bmcl.2014.07.012]
2. Stallinger A, Kretschmer N, Kleinegger F, Brvar L, Liegl-Atzwanger B, Prokesch A, Durchschein C, Bauer R, Deutsch A, Rinner B..  (2020)  β,β-Dimethylacrylshikonin Induces Apoptosis in Melanoma Cell Lines by NOXA Upregulation.,  83  (2): [PMID:31961147] [10.1021/acs.jnatprod.9b00719]
3. Valipour M..  (2022)  Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.,  235  [PMID:35367708] [10.1016/j.ejmech.2022.114314]

Source